Background.With the aging population and a rising incidence of squamous cell carcinoma of the head and neck (SCCHN), there is\nan emerging need for developing strategies to treat elderly patients. Patients and Methods.We retrospectively analyzed 158 patients\ntreated with definitive, concurrent chemoradiotherapy (CRT) for SCCHN. Clinicopathological characteristics, acute toxicities, and\noncological outcomes were compared between patients younger and older than (or of age equal to) 65, 70, and 75 years. Results.\nRT dose, chemotherapy regimen, and total chemotherapy dose were balanced between the groups. After a median follow-up of\n29 months, overall survival (OS), progression-free survival (PFS), local control rate, and distant metastasis-free survival stratified\nby age of �65, �70, or �75 years revealed no differences. The rate of acute toxicities was also not higher for older patients. Worse\nECOG performance score (ECOG 2-3) was associated with impaired OS (
Loading....